Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

S. Korea To Use AI In Drug Discovery

By Yonhap News Agency | June 8, 2018

South Korea will spearhead a project to develop a drug platform based on artificial intelligence (AI) and big data, the government said Thursday, in the latest effort to transform the country into a global biotech and medical industry hub.

A total of four research centers and universities—the Gwangju Institute of Science and Technology, Gyeongsang National University, Ewha Womans University and the Korea Research Institute of Chemical Technology (KRICT)—will join the project, the Ministry of Science and ICT said.

The researchers will work on the development of AI-supported platforms to search for possible candidate substances for new drugs that can precisely predict interactions between compounds, officials said.

The interaction between various compounds is an important consideration in both drug development and clinical application as it can help prevent potentially dangerous side effects.

The ministry forecasts that the developed platform, which will be revealed to the public sometime next year, will speed up drug discovery, and downsize research and development costs and further decrease failure rates in clinical trials.

“The platform will open a new horizon in the drug industry when technologies of bio, AI and big data meet,” said Kim Jeong-won, an ICT ministry official in charge of the project.

According to a new report published by Global Market Insights, the AI in the global drug development market is forecast to log an annual growth of 40 percent to reach $4 billion by 2024.

The ministry said KRICT will first build a substance data platform based on a database from both home and abroad.

Then, the three other participants will develop the AI platform based on deep learning and text mining technologies, it said.

(Source: Yonhap News Agency)


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE